



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		<b>Complete if Known</b>	
		Application Number	09/754,347
		Filing Date	January 5, 2001
		First Named Inventor	Daniel Gelber
		Art Unit	1651
		Examiner Name	Jean C. Witz
Sheet 1	of 1	Attorney Docket Number	XMP 2037

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	1	SMITH, Reversible Ovulatory Failure Associated..., <a href="http://www.fertilityplus.org/faq/nsaids.html">http://www.fertilityplus.org/faq/nsaids.html</a>	
	2	AKIL, Infertility May Sometimes be Associated..., <a href="http://www.fertilityplus.org/faq/nsaids.html">http://www.fertilityplus.org/faq/nsaids.html</a>	
	3	ZANGOLO, Effects of Acetylsalicylic Acid (Aspirin)..., <a href="http://www.fertilityplus.org/faq/nsaids.html">http://www.fertilityplus.org/faq/nsaids.html</a>	
	4	EPSEY, Rat Ovarian Prostaglandin Levels and..., <a href="http://www.fertilityplus.org/faq/nsaids.html">http://www.fertilityplus.org/faq/nsaids.html</a>	
	5	HARRIS, Prospective Study of Nonsteroidal..., Journal of Oncology 6(1), P. 71-73, 1995	
	6	SCHAPIRA, The Effects of AIDS on Breast..., Journal of Oncology 6(2), P. 433-435, 1995	
	7	Dehydroepiandrosterone (DHEA), <a href="http://www.mycustompak.com/healthNotes/Supp/DHEA.html">http://www.mycustompak.com/healthNotes/Supp/DHEA.html</a>	
	8	VAMEL, Effect of Plant Immunostimulant..., Arzneimittelforschung 35(9), P. 1437-1439, 1986	
	9	HALIM, Biochemical Effect of Antioxidants..., Ann Clin Biochem 34(6), P. 656-663, 1997	
	10	HYRB, The Effect of Extracts of the Roots..., Planta Med 61(1), P. 31-31, 1995	

Examiner Signature		Date Considered	6/29/03
--------------------	--	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.